Perjeta 420 MG/14 ML vial 14ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQWH8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,906
Award facts
- Contract value 100% obligated
- $4,905.81 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $4,905.81 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order, issued on January 2, 2026, with an ultimate completion date of January 26, 2026, operates under a firm fixed-price contract structure with no set-aside designation. This award falls under DMS Pharmaceutical Group's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract, a $30.3 billion acquisition strategy that DLA uses to source pharmaceutical products for Department of Defense healthcare operations globally.
DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier within the federal military medical system, holding a single-award indefinite delivery contract under the PPV-G GEN V initiative with a ceiling value of $499,999,999 extending through December 2036. The company's portfolio encompasses a comprehensive range of pharmaceuticals including branded and generic prescription medications, biologics, specialty oncology treatments, vaccines, and medical consumables. This delivery order for Perjeta, an oncology therapeutic, exemplifies the company's role in supporting the diverse and specialized pharmaceutical requirements of Department of Defense healthcare facilities worldwide, leveraging its small business status to compete effectively in federal pharmaceutical procurement while maintaining consistent contract performance.
Quick answers
Who was awarded contract SPE2DR26FQWH8?
SPE2DR26FQWH8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 2, 2026.
How much is contract SPE2DR26FQWH8 worth?
The government has obligated $4,906 on SPE2DR26FQWH8.
Is contract SPE2DR26FQWH8 an order under another contract?
Yes. SPE2DR26FQWH8 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWH8 competed?
The extent of competition for SPE2DR26FQWH8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award